What is the current stock price of INmune Bio, Inc. (INMB)?

As of the latest market data, INmune Bio, Inc. (INMB) is trading at $1.18. The stock has seen a loss of -7.81% today.

Does INmune Bio, Inc. (INMB) pay a dividend?

Based on current data, INmune Bio, Inc. does not have a confirmed active dividend policy.

What is the market cap of INmune Bio, Inc.?

The current market capitalization of INmune Bio, Inc. (INMB) is approximately unavailable.

INMB

INmune Bio, Inc.·Healthcare

1.18

7.813%(−0.10)

Market Closed

1.26

6.780%(+0.08)

After Hours

Last Updated: — ET

52W L: $1.0952W H: $11.64

INMB NEWS

defenseworld.net

Apr 2

INmune Bio, Inc. (NASDAQ:INMB) Receives Average Rating of “Hold” from Analysts

Shares of INmune Bio, Inc. (NASDAQ: INMB - Get Free Report) have been assigned a consensus rating of "Hold" from the six brokerages that are covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, two have issued a hold rating, one has given a buy rating and one has

seekingalpha.com

Mar 30

INmune Bio Inc. (INMB) Q4 2025 Earnings Call Transcript

globenewswire.com

Mar 30

INmune Bio Inc. Announces 2025 Results and Provides Business Update

BOCA RATON, Fla., March 30, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announces its financial results for the year ended December 31, 2025 and provides a business update.

seekingalpha.com

Feb 27

INmune Bio Inc. (INMB) Discusses XPro1595 Phase II MINDFuL Results and Registrational Strategy in Alzheimer's Disease Transcript

seekingalpha.com

Feb 27

INmune Bio Inc. (INMB) Discusses MissionEB Phase III Trial and CORDStrom as a Disease-Modifying Therapy for RDEB Transcript

globenewswire.com

Feb 23

INmune Bio to Detail XPro1595 Registrational Strategy in Upcoming Alzheimer's Webinar

Webinar on February 27 at 9:30 AM ET will have key opinion leaders discuss recent and upcoming clinical development of XPro1595 Webinar on February 27 at 9:30 AM ET will have key opinion leaders discuss recent and upcoming clinical development of XPro1595

Company Profile

INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2019-02-04

Beta

0.89

Websitewww.inmunebio.com↗